Verdant PhytoMed (Pty) Ltd Business Plan › Section 5 › Business Model & Revenue Strategy

5.1 Revenue Streams

Verdant PhytoMed operates a B2B export-oriented business model. Revenue is generated through three primary channels, with export contracts forming the backbone of the commercial strategy:

Figure

5.2 Go-To-Market Strategy

Phase 1: Foundation (Months 0–18)

• Execute pre-signed letters of intent (LOIs) with at least two EU-based pharmaceutical distributors

• Engage specialist cannabis export brokers in Germany, the UK, and Australia

• Attend key industry conferences (CannX Africa, CannaBusiness Europe, MJBizCon International)

Phase 2: Commercialisation (Months 18–36)

• Convert LOIs to binding offtake agreements with minimum volume commitments

• Establish direct relationships with German pharmaceutical wholesalers (e.g., Cansativa, Tilray Distribution)

• Launch pharmaceutical partnership programme targeting 3–5 API supply agreements

Phase 3: Scaling (Months 36–60)

• Expand into secondary markets (Australia, Israel, Brazil)

• Negotiate multi-year supply contracts with volume escalation clauses

• Explore vertical integration into finished dosage forms (capsules, tinctures)

5.3 Pricing Strategy

Pricing is benchmarked against international pharmaceutical cannabis commodity pricing, adjusted for South Africa’s cost advantage. The Company targets a premium positioning within the “pharmaceutical-grade” segment, differentiating on EU-GMP certification, batch-to-batch consistency, and full regulatory documentation packages.

This document contains proprietary and confidential information. Distribution without written consent is prohibited.